

**Editorial****Recent improvements in mRNA and immunogenicity****Abdul M. Gbaj**

Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Tripoli, Libya

Corresponding author: abdulgbaj1@hotmail.com
<https://orcid.org/0000-0003-4859-9158>**Received:** 04-06-2022, **Published:** 30-06-2022

Copyright © 2022 Gbaj AM. This is an open access article distributed under the **Creative Commons Attribution License**, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

HOW TO CITE THIS

Gbaj AM (2022) Recent improvements in mRNA and immunogenicity. *Mediterr J Pharm Pharm Sci.* 2 (2): 1 - 2.
<https://doi.org/10.5281/zenodo.0000000>.

Keywords: COVID-19, immune response, immunogenicity, mRNA, vaccine

Vaccines avoid many illnesses and save many lives every year. As a result of common vaccine use, the smallpox virus has entirely been eradicated and the occurrence of measles, polio and other childhood diseases have considerably been abridged around the world. Classical vaccine strategies, for instance inactivated pathogen, live attenuated and subunit vaccines, offer strong protection against diversity of hazardous diseases. In spite of this achievement, there remain chief obstacles to vaccine development against a diversity of infectious pathogens, particularly those better able to avoid the adaptive immune response. Furthermore, for most emerging virus vaccines, the main barrier is not the efficiency of usual approaches but the requirements for more rapid development and large-scale use. Nucleic acid therapeutics have appeared as hopeful option to classical vaccine approaches. The messenger ribonucleic acid (mRNA) is the intermediate step connecting the translation of protein-encoding DNA and the manufacturing of proteins by ribosomes in the cytoplasm. Global efforts have been taken to develop SARS-CoV-2 vaccines since the initiation of the current COVID-19 pandemic. The mRNA vaccines (i.e., mRNA-1273 and BNT162b2) are the most commonly approved vaccines worldwide

which are utilized in different clinical trials on a global scale [1]. More recent, a variety of mRNA vaccine platforms have recently been developed and validated [2]. Engineering of the RNA sequence has made synthetic mRNA further translatable than ever before. Exogenous mRNA is intrinsically immunostimulatory, as it is acknowledged by an assortment of cell surface, endosomal and cytosolic innate immune receptors. Depending on the beneficial function, this characteristic of mRNA could be beneficial or harmful. It is potentially beneficial for vaccination because in some cases it may offer adjuvant activity to drive dendritic cell (DC) maturation and thus bring out strong T and B cell immune responses. Though, innate immune sensing of mRNA connected with the inhibition of antigen expression and might unconstructively affect the immune response. Although the inconsistent effects of innate immune sensing on different formats of mRNA vaccines are partly understood, some progress has recently been made in the COVID-19 vaccine in elucidating these phenomena [3]. The mRNA vaccines work by introducing a portion of mRNA that corresponds to a viral protein, frequently

a small piece of a protein found on the virus's outer membrane. As part of a usual immune response, the immune system recognizes that the protein is foreign and produces specialized proteins called antibodies. Antibodies help protect the body against infection by recognizing individual viruses or other pathogens, attaching to them and allocating the pathogens for destruction. Once produced, antibodies stay in the body, even after the body has rid itself of the pathogen, with the intention that the immune system can rapidly react if exposed again. If a person is exposed to a virus after receiving mRNA vaccination

for it, antibodies can quickly recognize it, attach to it, and mark it for destruction before it can cause serious illness. mRNA vaccines have emerged as promising alternatives to provide protection against COVID-19 due to their high potency with the capacity for rapid development and low-cost production. Now, the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) and Moderna COVID-19 vaccine (Spikevax™) use mRNA to stimulate an immune response that can protect against future COVID-19 infection.

Author contribution: *Gbaj AM* is sole author who conceived, designed, collected the data, checking and approving the final version of the manuscript.

Conflict of interest: The author declares that the research was conducted in absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical issues: Including plagiarism, informed consent, data fabrication or falsification and double publication or submission have completely been observed by the author.

References

1. Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich PY, Taylor BS, Simand PF, Patel D, Wang J, Labidi-Galy I, Fertani S, RJ, Sandoval J, Mesa R, Kate Lathrop R, Mach N, Dimpy P Shah DP (2021) Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. *Cancer Cell*. 39 (8): 1091-1098. doi: 10.1016/j.ccell.2021.06.009.
2. Salleh MZ, Norazmi MN, Deris ZZ (2022) Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. *Biochemistry, Biophysics and Molecular Biology section - Peer Journal*. 10: e13083. doi: 10.7717/peerj.13083.
3. Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, Ghadery AH, Shabani M, Tabary M, Aryannejad A, Seyed Alinaghi SA, Rezaei N (2022) Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. *European Journal of Medical Research*. 27: 23. doi.org/10.1186/s40001-022-00648-5.